gene_symbol
CD3E
hgnc_id
HGNC:1674
binding_type
antigen recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Elranatamab binds CD3ε on T cells to activate and redirect them to BCMA+ myeloma cells; the T cells then kill BCMA-expressing targets via perforin/granzyme. CD3+ T cells are not the cytotoxic targets.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
TCR–CD3 complex component on T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06152575
disease_id_num_tar_ref
61
drug_id_num_tar_ref
147